Clinical Trials Browser

Carcinoma, Ovarian Epithelial × mirvetuximab soravtansine × Gynecologic × Clear all

NCT06890338 2026-02-24

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 Recruiting

140 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07218809 2026-01-16

TREVI-OC-01

Phase 3 Recruiting

1,100 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

Phase 3 Completed

453 enrolled 18 charts 1 FDA

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04296890 2024-08-07

SORAYA

Phase 3 Completed

106 enrolled 14 charts 1 FDA

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02606305 2024-06-14

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Completed

264 enrolled 41 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05622890 2022-11-21

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Phase 3 Unknown

35 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02631876 2020-10-14

FORWARD I

Phase 3 Completed

366 enrolled 20 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms